Direct factor Xa inhibitor in the prevention of thromboembolism
Venous thromboembolism is the third most common cause of vascular death after myocardial infarction and stroke, and is associated with considerable morbidity and premature mortality. The incidence of the most serious consequence of venous thromboembolism, fatal pulmonary embolism, ranges from 0.01%...
Main Authors: | Viktor Meretskyi, Iryna Meretska, Vasyl Pertsovych |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2019-01-01
|
Series: | Health Problems of Civilization |
Subjects: | |
Online Access: | https://www.termedia.pl/Direct-factor-Xa-inhibitor-in-the-prevention-of-thromboembolism,99,34268,1,1.html |
Similar Items
-
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
by: Rupert Bauersachs, et al.
Published: (2020-05-01) -
Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry
by: Victoria Speed, et al.
Published: (2021-12-01) -
Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
by: Shohei Migita, et al.
Published: (2023-08-01) -
Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry
by: Stephanie Müller, et al.
Published: (2022-10-01) -
Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis
by: Olivia S. Costa, et al.
Published: (2020-04-01)